Experts release the first study to test GlaxoSmithKline's (GSK) investigational RTS, S/AS02D malaria vaccine in African infants
At a forum today in Seattle, experts released the first study to test GlaxoSmithKline's (GSK) investigational RTS, S/AS02D malaria vaccine in African infants. It serves as the first proof of concept in this population that the vaccine has a promising safety and tolerability profile and reduces malaria parasite infection and illness due to malaria, according to a paper published today online in The Lancet.
Of the more than one million Africans who die from malaria each year most are children under five years of age, according to the Roll Back Malaria Partnership's World Malaria Report 2005. Malaria also contributes significantly to anaemia in children and pregnant women, adverse birth outcomes such as spontaneous abortion, stillbirth, premature delivery and low birth weight, and overall child mortality.
Read the press release